N. Vagulienė, “THE PEMBREIZH MULTICENTER REAL-LIFE COHORT STUDY: FIRST LINE PEMBROLIZUMAB FOR NON-SMALL CELL LUNG CANCER PATIENTS WITH PD-L1 ≥50%”, PIA, vol. 4, no. 2, pp. 164-167, Sep. 2020.